Hemovent has introduced next-generaion MOBYBOX system for clinicians at the 29th Annual ELSO Conference in the US.
The event is being held between 13 and 16 September in Scottsdale, Arizona.
MOBYBOX has recently and successfully completed a GLP-standardized in vivo study for long-term (7 days) use.
MOBYBOX is based on Hemovent’s novel and portable Bionique artificial lung technology platform, designed for a wide range of indications: from ExtraCorporeal Life Support (ECLS) to ExtraCorporeal CO2 Removal (ECCO2R).
Hemovent co-founder and CEO Christof Lenz said: “We are extremely pleased to be introducing MOBYBOX at one of the leading scientific meetings in the world. ELSO is an international nonprofit consortium of healthcare institutions that are dedicated to the development and evaluation of novel therapies for support of failing organ systems.
“We expect that the outstanding results from our recent in vivo study will create quite a buzz at ELSO. When our initial technology application, MOBYBOX, is commercially available, it will simplify ECMO usage, not only for life support applications (ECLS) but also as an effective therapy for respiratory failure indications including ECCO2R protocols,”
These types of applications — ECLS and ECCO2R — are also known as ExtraCorporeal Membrane Oxygenation (ECMO): the establishment of an artificial external blood circuit with a pump and gas exchanger system in order to support the lung function only or even establish a full cardiopulmonary bypass.
Hemovent is an emerging medical device company that has developed a self-contained and easy-to-use artificial lung for ExtraCorporeal Membrane Oxygenation (ECMO) /ExtraCorporeal Life Support (ECLS) applications designed to support or replace heart and lung function in the event of cardiac and/or respiratory failure.
Source: Company Press Release